Company / Capital Returned to Shareholders
Fulgent Genetics, Inc. Capital Returned to Shareholders History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$10.9M
FY2025
5-year range
$225.0K / $74.3M
FY2021-FY2025
Trend
+4737.3%
vs FY2024
Sector context
#88 of 108
Health Care
What the data says
Capital Returned to Shareholders changed +4737% YoY in FY2025, a notable deviation from the 6-year average annual change of +20755%.
Based on SEC 10-K filings.
$11M in FY2025 with a 5-year CAGR of +181.1%.
Declined from $74M to $11M over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -47.3%
- 5-Year CAGR
- +181.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 108This company $10.9M Sector average $744.4M
▼
-98.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +181.1%, indicating consistent growth.
- In FY2025, capital returned to shareholders increased 4737.3% year-over-year.
- Ranks #88 out of 108 companies in the Health Care sector.
- Peak capital returned to shareholders was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.9M | +4737.3% |
| FY2024 | $225.0K | -99.7% |
| FY2023 | $74.3M | +0.0% |
| FY2022 | $74.3M | - |
| FY2021 | - | - |
| FY2020 | $62.0K | +195.2% |
| FY2019 | $21.0K | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | $12.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026